Vanda Pharmaceuticals Inc. (OQ:VNDA)

Apr 30, 2024 04:30 pm ET
Apr 25, 2024 08:05 am ET
Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda Pharmaceuticals
Shareholder Capital LLC (together with its members and affiliates, “ShareCap”), a significant shareholder of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) (“Vanda” or the “Company”) holding over 200,000 shares of the Company’s common stock, announced...
Apr 22, 2024 07:12 pm ET
Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation
WASHINGTON, April 22, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ® Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp. 
Apr 17, 2024 10:21 am ET
Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan
WASHINGTON, April 17, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today announced that its Board of Directors (the "Board") has adopted a limited duration stockholder rights plan (the "Rights Plan") to protect stockholder interests and maximize value for all stockholders. The Rights Plan is effective immediately.
Apr 17, 2024 09:02 am ET
Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak
Board Determined Unsolicited Takeover Proposals Significantly Undervalue the Company
Apr 02, 2024 06:10 pm ET
Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
Fanapt® Treatment is Now Available to Adult Patients for the Acute Treatment of Manic or Mixed Episodes Associated with Bipolar I Disorder
Mar 31, 2024 11:43 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceutical Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The...
Mar 25, 2024 09:31 am ET
Thinking about buying stock in Intellicheck, Vanda Pharmaceuticals, Dave Inc, Invivyd, or Dream Finders Homes?
NEW YORK, March 25, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IDN, VNDA, DAVE, IVVD, and DFH.
Mar 23, 2024 04:41 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceutical Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA).   Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....
Mar 15, 2024 04:37 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc. – VNDA
Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The...
Feb 23, 2024 08:31 am ET
Thinking about buying stock in Maravai Lifesciences, Abercrombie & Fitch, elf Beauty, IONQ, or Vanda Pharmaceuticals?
NEW YORK, Feb. 23, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRVI, ANF, ELF, IONQ, and VNDA.
Feb 07, 2024 03:02 pm ET
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
Full year 2023 revenues were $192.6 millionPONVORY® acquisition completed in Q4 2023 and transition ongoing3 FDA PDUFA target action dates in 2024Ended 2023 with approximately $388 million in cash and cash equivalentsWASHINGTON, Feb. 7, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2023.
Feb 05, 2024 07:00 am ET
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
WASHINGTON, Feb. 5, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that on February 4, 2024, it received a notification from the U.S. Food and Drug Administration (FDA) stating that as part of its ongoing review of Vanda's supplemental New Drug Application (sNDA) for HETLIOZ® (tasimelteon) in the treatment of insomnia characterized by difficulties with sleep initiation, the FDA has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time. No deficiencies were disclosed by the FDA in the notifi
Jan 31, 2024 08:00 am ET
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis
WASHINGTON, Jan. 31, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate VTR-297 for the treatment of onychomycosis.
Jan 30, 2024 11:35 am ET
Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024
WASHINGTON, Jan. 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the United States District Court for the District of Columbia granted Vanda's motion for summary judgment on its claim against the United States Food and Drug Administration (FDA) for unlawfully delaying a hearing on the approvability of Vanda's supplemental new drug application (sNDA) for HETLIOZ® to treat jet lag disorder (Vanda Pharmaceuticals Inc. v. FDA, case no. 1:22-cv-2275-CJN).
Jan 29, 2024 06:00 pm ET
Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024
WASHINGTON, Jan. 29, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the United States District Court for the District of Columbia granted Vanda's motion for summary judgment on its claim against the United States Food and Drug Administration (FDA) for unlawfully delaying a hearing on the approvability of Vanda's supplemental new drug application (sNDA) for HETLIOZ® to treat jet lag disorder (Vanda Pharmaceuticals Inc. v. FDA, case no. 1:22-cv-2275-CJN).
Jan 25, 2024 09:05 pm ET
Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S.
WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Patent and Trademark Office has issued a notice of allowance for its PONVORY® (ponesimod) patent application, number 17/962,968, covering methods for reducing clinical management events before or during the treatment of multiple sclerosis and methods for reinitiating treatment after missed doses. When issued, this patent is anticipated to expire on October 10, 2042. Upon issuance, Vanda intends to list this patent in the U.S. Food and Drug Administration publication Appro
Jan 25, 2024 12:07 pm ET
Vanda Pharmaceuticals announces the publication of an article on "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical
WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of an article titled "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial" in the Clinical Gastroenterology and Hepatology Journal1 which follows a previously published study of tradipitant in the treatment of gastroparesis in 2021.2 The findings of this pivotal phase III study are included in the New Drug Application for tradipitant in the treatment of gastroparesis in adults submi
Jan 23, 2024 08:15 am ET
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S
WASHINGTON, Jan. 23, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate VCA-894A for the treatment of a patient with Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), caused by cryptic splice site variants within the IGHMBP2 gene.
Jan 19, 2024 02:56 pm ET
Federal Court Allows Vanda Pharmaceuticals' Lawsuit to Proceed Against the U.S. Food and Drug Administration
WASHINGTON, Jan. 19, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the United States Court of Federal Claims in Washington, D.C. denied in part the government's motion to dismiss Vanda's claim against the United States for the Food and Drug Administration's (FDA) uncompensated taking of Vanda's trade secrets and confidential information (Vanda Pharmaceuticals Inc. v. USA, case no. 1:23-cv-00629-AOB). Vanda is seeking compensation from the United States for the takings it contends occurred through the FDA's improper communication and disclosure of
Jan 17, 2024 02:46 pm ET
Vanda Pharmaceuticals announces the publication of Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study in the Journal of Clinical Psychiatry
WASHINGTON, Jan. 17, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of an article titled "Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study" in the Journal of Clinical Psychiatry.1 The findings of this pivotal study have been submitted to the U.S. Food and Drug Administration (FDA) as part of Vanda's supplemental New Drug Application for Fanapt® in the treatment of bipolar I disorder in adults. The FDA has set a Prescription Drug User Fee Act target action date of April 2, 2024 for its decisio
Jan 12, 2024 11:21 am ET
Vanda Pharmaceuticals Comments on FDA's Recently Announced Guidance on Communication with Health Care Professionals Regarding FDA-Approved Drugs
WASHINGTON, Jan. 12, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) submitted a comment letter (here) on January 5, 2024, regarding the FDA's recently announced policy—by way of a draft guidance document—that substantially restricts drug manufacturers' ability to communicate truthful, non-misleading information about FDA-approved drugs.
Jan 04, 2024 03:30 pm ET
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
WASHINGTON, Jan. 4, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 9, 2024.  A corporate presentation is scheduled for 9:45 a.m. Pacific Time (12:45 p.m. Eastern Time).
Dec 07, 2023 06:00 am ET
Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis
WASHINGTON, Dec. 7, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has acquired U.S. and Canadian rights to PONVORY® (ponesimod) from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company. PONVORY® is approved by the U.S. Food and Drug Administration (FDA) and Health Canada to treat adults with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. PONVORY® has a proven safety profile with over 10 years of data.
Dec 04, 2023 05:00 pm ET
Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis
WASHINGTON, Dec. 4, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of Vanda's New Drug Application (NDA) for tradipitant for the treatment of symptoms of gastroparesis.
Nov 09, 2023 03:30 pm ET
Vanda Pharmaceuticals Announces Participation at November 2023 Investor Conferences
WASHINGTON, Nov. 9, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in November 2023:
Nov 08, 2023 03:01 pm ET
Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results
Total revenues in the first nine months of 2023 were $147.4 millionVanda provides update on pipeline advancements and regulatory plansWASHINGTON,  Nov. 8, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2023.
Nov 01, 2023 05:00 pm ET
Oct 20, 2023 07:00 am ET
Vanda Pharmaceuticals Intends to Petition the U.S. Supreme Court in its HETLIOZ® ANDA Litigation
WASHINGTON, Oct. 20, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced its intention to file a petition for a writ of certiorari in its HETLIOZ® Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp.
Oct 05, 2023 06:30 pm ET
Vanda Pharmaceuticals Announces Participation in the Jefferies Inaugural Biotech CNS/Neuro Summit
WASHINGTON, Oct. 5, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit in New York City on Wednesday, October 11, 2023. A corporate presentation is scheduled for 1:30 p.m. Eastern Time.
Jul 27, 2023 04:01 pm ET
Vanda Pharmaceuticals Reports Second Quarter 2023 Financial Results
Q2 2023 total revenues were $46.1 millionTotal revenues in the first six months of 2023 were $108.6 millionVanda provides update on pipeline advancements and regulatory plansWASHINGTON, July 27, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2023.
Jul 20, 2023 04:30 pm ET
Jun 05, 2023 07:00 am ET
Vanda Pharmaceuticals Announces Participation in the Jefferies 2023 Global Healthcare Conference
WASHINGTON, June 5, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies 2023 Global Healthcare Conference in New York City on Friday, June 9, 2023. A corporate presentation is scheduled for 12:15 p.m. Eastern Time.
Jun 01, 2023 09:41 pm ET
Vanda Pharmaceuticals Announces Presentations at SLEEP 2023
WASHINGTON, June 1, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2023, to be held in Indianapolis, IN from June 3 – 7, 2023.
Jun 01, 2023 09:31 pm ET
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S
WASHINGTON, June 1, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VCA-894A for the treatment of Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), caused by cryptic splice site variants within IGHMBP2.
May 25, 2023 07:00 am ET
Vanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion Sickness
WASHINGTON, May 25, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the results from its Phase III study of tradipitant in motion sickness, confirming the previously reported results demonstrating that tradipitant is effective in the prevention of vomiting associated with motion sickness. The Phase III study was conducted in real-world conditions on boats in the coastal waters of the United States (U.S.).
May 10, 2023 02:26 pm ET
Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Appeal
WASHINGTON, May 10, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today responded to the ruling in its Hetlioz® Abbreviated New Drug Application appeal.
May 04, 2023 06:00 pm ET
Vanda Pharmaceuticals Announces Presentations at DDW 2023
WASHINGTON, May 4, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at Digestive Disease Week (DDW) 2023, to be held in Chicago, IL and online from May 6-9, 2023.
May 03, 2023 04:01 pm ET
Vanda Pharmaceuticals Reports First Quarter 2023 Financial Results
Q1 2023 total revenues were $62.5 millionVanda provides update on three upcoming regulatory submissionsWASHINGTON, May 3, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2023.
May 02, 2023 12:46 pm ET
Vanda Pharmaceuticals Sues Federal Government for Misappropriation of Trade Secrets and Confidential Information
WASHINGTON, May 2, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced its action against the federal government for the uncompensated taking and misuse of Vanda's trade secrets and confidential information. Vanda alleges that the U.S. Food and Drug Administration (FDA) improperly provided confidential details from Vanda's drug master files for its products, HETLIOZ® and Fanapt®, to generic drug manufacturers during the FDA's review of the manufacturers' Abbreviated New Drug Applications. The action was filed in the United States Court of Federal Claims and
Apr 27, 2023 06:00 pm ET
Mar 28, 2023 01:26 pm ET
Vanda Prevails in Jet Lag Litigation Against the FDA
WASHINGTON, March 28, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced a win in its jet lag FOIA litigation against the FDA.
Mar 17, 2023 07:00 am ET
Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors
WASHINGTON, March 17, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the appointment of Tage Honoré, Ph.D., D.Sc. to its Board of Directors effective March 15, 2023. Following Dr. Honoré's appointment, Vanda's Board of Directors is now comprised of six directors, five of whom are independent.
Feb 08, 2023 03:01 pm ET
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
Q4 2022 total revenues were $64.5 millionFull year 2022 revenues were $254.4 millionVanda provides update on pipeline advancements and upcoming milestonesWASHINGTON, Feb. 8, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2022.
Jan 06, 2023 08:00 am ET
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
WASHINGTON, Jan. 6, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P. Morgan Healthcare Conference in San Francisco, California on Thursday, January 12, 2023.  A corporate presentation is scheduled for 12:00 p.m. Pacific Time (3:00 p.m. Eastern Time).
Dec 19, 2022 06:00 am ET
Fanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study
Supplemental New Drug Application (sNDA) planned for 2023WASHINGTON, Dec. 19, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today reported positive results in a Phase III clinical study of Fanapt® (iloperidone tablets), a novel atypical antipsychotic, in the treatment of acute manic and mixed episodes associated with bipolar I disorder in adults. Fanapt® is currently approved by the FDA for the treatment of schizophrenia in adults.
Dec 16, 2022 01:54 pm ET
Vanda Pharmaceuticals Provides an Update to HETLIOZ® ANDA Litigation Appeal: Federal Circuit grants motion to temporarily enjoin generic launch
WASHINGTON, Dec. 16, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its appeal of the recent HETLIOZ® ANDA litigation ruling.
Dec 13, 2022 02:15 pm ET
Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Litigation
WASHINGTON, Dec. 13, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today responded to the ruling in its HETLIOZ® ANDA Litigation.
Dec 02, 2022 06:00 am ET
Vanda Pharmaceuticals Reports Results in a Phase II Clinical Study of VQW-765 in the Treatment of Acute Performance Anxiety
WASHINGTON, Dec. 2, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today reported results in a Phase II clinical study of VQW-765, a novel small molecule alpha 7 nicotinic acetylcholine receptor (α7-nAChR) partial agonist, in the treatment of acute performance anxiety in social situations, such as public speaking.
Nov 08, 2022 07:30 pm ET
Vanda Pharmaceuticals Announces Participation at November 2022 Investor Conferences
WASHINGTON, Nov. 8, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in November 2022:
Nov 02, 2022 04:01 pm ET
Vanda Pharmaceuticals Reports Third Quarter 2022 Financial Results
Q3 2022 total revenues were $65.3 millionTotal revenues in the first nine months of 2022 were $189.9 millionVanda provides update on pipeline advancements and upcoming milestonesWASHINGTON, Nov. 2, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2022.
Oct 26, 2022 06:00 pm ET
Oct 21, 2022 02:00 pm ET
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera
WASHINGTON, Oct. 21, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VPO-227 for the treatment of cholera.
Sep 29, 2022 04:30 pm ET
Vanda Pharmaceuticals and OliPass Announce Strategic Partnership to Develop Antisense Oligonucleotide Therapeutics
WASHINGTON, Sept. 29, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and OliPass Corporation (OliPass) (KOSDAQ: 24460) today announced that they have entered into a research and development collaboration agreement to jointly develop a set of antisense oligonucleotide (ASO) molecules based on OliPass' proprietary modified peptide nucleic acids. This innovative partnership leverages the respective strengths of Vanda and OliPass to support the development of ASO-based precision medicine therapeutics and potentially create compelling value opportunities for both companies
Sep 08, 2022 06:00 pm ET
Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference
WASHINGTON, Sept. 8, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the company will participate in the H.C. Wainwright Global Investment Conference in New York City on Wednesday, September 14, 2022. A corporate presentation is scheduled for 8:30 a.m. Eastern Time.
Sep 07, 2022 06:38 pm ET
VANDA PHARMACEUTICALS ANNOUNCES NOTICE OF OPPORTUNITY FOR AN FDA HEARING ON THE sNDA FOR HETLIOZ® IN JET LAG DISORDER
WASHINGTON, Sept. 7, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the notice of opportunity for an FDA hearing on Vanda's Supplemental New Drug Application (sNDA) for HETLIOZ® (tasimelteon) to treat jet lag disorder.
Aug 03, 2022 04:01 pm ET
Vanda Pharmaceuticals Reports Second Quarter 2022 Financial Results
Q2 2022 total revenues were $64.4 millionTotal revenues in the first six months of 2022 were $124.6 millionVanda provides update on pipeline advancements and upcoming milestonesWASHINGTON, Aug. 3, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2022.
Jul 27, 2022 05:30 pm ET
Jun 02, 2022 04:30 pm ET
Vanda Pharmaceuticals Announces Participation in the Jefferies 2022 Global Healthcare Conference
WASHINGTON, June 2, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies 2022 Global Healthcare Conference in New York City on Thursday, June 9, 2022. A corporate presentation is scheduled for 3:30 p.m. Eastern Time.
May 31, 2022 06:00 pm ET
Vanda Pharmaceuticals Announces Presentations at SLEEP 2022
WASHINGTON, May 31, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2022, to be held in Charlotte, North Carolina from June 4-8, 2022.
May 19, 2022 07:00 pm ET
Vanda Pharmaceuticals Announces Presentations at DDW 2022
WASHINGTON, May 19, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at Digestive Disease Week (DDW) 2022, to be held in San Diego, CA and online from May 21-24, 2022.
May 05, 2022 04:10 pm ET
Vanda Pharmaceuticals Reports First Quarter 2022 Financial Results
WASHINGTON , May 5, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2022.
May 04, 2022 04:30 pm ET
Vanda Pharmaceuticals Announces Participation in the BofA Securities 2022 Healthcare Conference
WASHINGTON, May 4, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada on Tuesday, May 10, 2022. A corporate presentation is scheduled for 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time).
Apr 28, 2022 05:00 pm ET
Feb 23, 2022 03:01 pm ET
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
WASHINGTON, Feb. 23, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2021.
Feb 17, 2022 05:00 pm ET
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
WASHINGTON, Feb. 17, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2021 on Wednesday, February 23, 2022, after the market closes.  
Feb 04, 2022 06:00 am ET
Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in Gastroparesis
WASHINGTON, Feb. 4, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced results from its Phase III clinical study, VP-VLY-686-3303, evaluating the efficacy and safety of tradipitant in treating the symptoms of gastroparesis. The study did not meet its prespecified primary endpoint which was the difference between drug and placebo on the change of the severity of nausea from baseline at week 12 of treatment. Both treatment arms showed significant improvements from baseline on nausea as well as the other core symptoms of gastroparesis.
Jan 14, 2022 07:35 am ET
Vanda Pharmaceuticals Settles HETLIOZ® Patent Litigation with MSN
WASHINGTON, Jan. 14, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it has entered into a License Agreement (the License Agreement) with MSN Pharmaceuticals Inc., MSN Laboratories Private Limited (together MSN) and Impax Laboratories LLC (Impax) to resolve Vanda's patent litigation against MSN regarding MSN's Abbreviated New Drug Application seeking approval of its generic version of Vanda's HETLIOZ® (tasimelteon).
Nov 10, 2021 05:30 pm ET
Vanda Pharmaceuticals Announces Participation at November 2021 Investor Conferences
WASHINGTON, Nov. 10, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Vanda management will participate at the following upcoming investor conferences in November 2021:
Nov 03, 2021 04:01 pm ET
Vanda Pharmaceuticals Reports Third Quarter 2021 Financial Results
WASHINGTON, Nov. 3, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2021.
Oct 27, 2021 05:30 pm ET
Vanda Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 3, 2021
WASHINGTON, Oct. 27, 2021 /PRNewswire/ --  Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2021 on Wednesday, November 3, 2021, after the market closes.
Oct 14, 2021 04:30 pm ET
Vanda Pharmaceuticals Announces Participation at Evercore ISI's Catalyst Day
WASHINGTON, Oct. 14, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at Evercore ISI's Catalyst Day on Monday, October 18, 2021. Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board, will take part in a virtual fireside chat at 1:30 PM ET.
Sep 07, 2021 08:30 pm ET
Vanda Pharmaceuticals Announces Participation at the Citi 16th Annual BioPharma Virtual Conference
WASHINGTON, Sept. 7, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Vanda's management will participate at the Citi 16th Annual BioPharma Virtual Conference taking place between September 8 and September 10, 2021. Vanda management will host investor meetings. Vanda has updated its corporate presentation, which may be accessed on Vanda's website, www.vandapharma.com, by clicking on the Investors tab and following the Corporate Presentation link.
Aug 03, 2021 07:00 am ET
Vanda Pharmaceuticals Closes Enrollment In The ODYSSEY Study Comparing Tradipitant And Placebo In Hospitalized COVID-19 Pneumonia Patients
WASHINGTON, Aug. 3, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that enrollment has closed in the ODYSSEY study comparing tradipitant and placebo in hospitalized COVID-19 pneumonia patients.
Jul 28, 2021 04:01 pm ET
Vanda Pharmaceuticals Reports Second Quarter 2021 Financial Results
WASHINGTON, July 28, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2021.
Jul 23, 2021 03:26 pm ET
Notice of Settlement of Derivative Suit
Bragar Eagel & Squire P.C. announces the proposed settlement of the derivative action captioned In re Vanda Pharmaceuticals Inc. Derivative Litigation, Case No. 1:19-cv-04293-FB-LB in the United States District Court for the Eastern District of New...
Jul 21, 2021 04:30 pm ET
Vanda Pharmaceuticals to Announce Second Quarter 2021 Financial Results on July 28, 2021
WASHINGTON, July 21, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2021 on Wednesday, July 28, 2021, after the market closes.
Apr 25, 2021 02:00 am ET
Lifshitz Law Firm, P.C. Announces Investigations of Jeld-Wen Holding, Inc. (NYSE: JELD), Merit Medical Systems, Inc. (NasdaqGS: MMSI), RCI Hospitality Holdings, Inc. (NasdaqGM: RICK), and Vanda Pharma
Jeld-Wen Holding, Inc. (NYSE: JELD) Lifshitz Law Firm, P.C. announces that on October 26, 2020, the Court issued an Order denying Defendants' Motions to Dismiss a putative class action complaint. The Complaint alleges that throughout the Class...
Apr 16, 2021 02:33 pm ET
Lifshitz Law Firm, P.C. Announces Investigations of Inovio Pharmaceuticals, Inc. (NasdaqGS: INO), Merit Medical Systems, Inc. (NasdaqGS: MMSI), RCI Hospitality Holdings, Inc. (NasdaqGM: RICK), and Van
Inovio Pharmaceuticals, Inc. (NasdaqGS: INO) Lifshitz Law Firm, P.C. announces that on February 16, 2021, the Court issued an Order granting in part and denying in part Defendants' Motion to Dismiss a putative class action complaint alleging that...
Mar 18, 2021 04:26 pm ET
Shuman, Glenn & Stecker Investigates Vanda Pharmaceuticals Inc.
Shuman, Glenn & Stecker announces that it is investigating potential claims against certain officers and directors of Vanda Pharmaceuticals, Inc. (“Vanda” or the “Company”) (Nasdaq:
Mar 17, 2021 01:56 pm ET
SHAREHOLDER ALERT: Barr Law Group Investigating VNDA, VLDR, RIDE, and ABT; Shareholders are Encouraged to Contact the Firm
National law firm Barr Law Group is investigating the actions of the officers and board of directors of Vanda Pharmaceuticals Inc., Velodyne Lidar, Inc., Lordstown Motors Corporation, and Abbott Laboratories.   If you are a current owner of shares...
Mar 12, 2021 10:50 pm ET
VANDA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Vanda Pharmaceuticals Inc. - VNDA
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Vanda Pharmaceuticals Inc. (NasdaqGM: VNDA).
Mar 11, 2021 01:52 pm ET
Shareholder Alert: Robbins LLP Announces that Vanda Pharmaceuticals Inc. (VNDA) Class Action Survives Motion to Dismiss
Shareholder rights law firm Robbins LLP announces that Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) may face damages caused by a pending securities lawsuit. Vanda Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of central nervous system d
Feb 12, 2021 10:00 am ET
Thinking about buying stock in Sundial Growers, Diffusion Pharmaceuticals, Vanda Pharmaceuticals, Aurora Cannabis, or Globalstar?
NEW YORK, Feb. 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, DFFN, VNDA, ACB, and GSAT.
Feb 10, 2021 03:01 pm ET
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
WASHINGTON, Feb. 10, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2020.
Feb 02, 2021 03:30 pm ET
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 10, 2021
WASHINGTON, Feb. 2, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2020 on Wednesday, February 10, 2021, after the market closes.  
Dec 01, 2020 05:00 pm ET
FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome
WASHINGTON, Dec. 1, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved HETLIOZ® (tasimelteon) capsule and liquid formulations for the treatment of adults and children, respectively, with nighttime sleep disturbances associated with Smith-Magenis Syndrome (SMS). SMS is a rare neurodevelopmental disorder, a defining feature of which is an "inverted" circadian rhythm, making it extremely difficult for patients with SMS to sleep during the night. HETLIOZ® is the first FDA-approved medication for pat
Oct 28, 2020 04:01 pm ET
Vanda Pharmaceuticals Reports Third Quarter 2020 Financial Results
WASHINGTON, Oct. 28, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2020.
Oct 26, 2020 04:01 pm ET
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VSJ-110 for Allergic Conjunctivitis
WASHINGTON, Oct. 26, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) activator VSJ-110 (previously known as CFTRact-K267) for the treatment of allergic conjunctivitis.
Oct 21, 2020 04:45 pm ET
Vanda Pharmaceuticals to Announce Third Quarter 2020 Financial Results on October 28, 2020
WASHINGTON, Oct. 21, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2020 on Wednesday, October 28, 2020, after the market closes.  
Aug 05, 2020 04:01 pm ET
Vanda Pharmaceuticals Reports Second Quarter 2020 Financial Results
WASHINGTON, Aug. 5, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2020.
Aug 03, 2020 07:00 am ET
FDA Accepts and Grants Priority Review of Vanda's Applications for HETLIOZ® (tasimelteon) in the Treatment of Smith-Magenis Syndrome
WASHINGTON, Aug. 3, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review Vanda's applications for Smith-Magenis Syndrome (SMS). The applications include a Supplemental New Drug Application (sNDA) for HETLIOZ® capsules and a New Drug Application (NDA) for the liquid formulation of HETLIOZ® for the treatment of adults and children, respectively, with Smith-Magenis Syndrome (SMS). The FDA has set December 1, 2020 as the target date for its decision under the Prescription Drug User
Jul 29, 2020 05:00 pm ET
Vanda Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020
WASHINGTON, July 29, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2020 on Wednesday, August 5, 2020, after the market closes.
Jul 21, 2020 04:04 pm ET
Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Vanda Pharmaceuticals Inc. (VNDA)
Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) for breaches of fiduciary duties, unjust enrichment, and violations of the Securities Exchange Act of 1934. Vanda Pharmaceuticals Inc. is a biopharmaceutical company that focus
Jul 13, 2020 04:30 pm ET
FDA grants authorization for Individual Patient Expanded Access Protocol for the use of tradipitant for gastroparesis
WASHINGTON, July 13, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that the U.S. Food and Drug Administration (FDA) has authorized a single patient in an Individual Patient Expanded Access protocol (VP-VLY-686-3303).  This patient had previously participated in a randomized study of tradipitant in gastroparesis for 12 weeks.  The patient and treating physician requested expanded access to continue treatment beyond 12 weeks, as the treating physician had judged that tradipitant was the only treatment that effectively managed the patient's gastroparesis
May 26, 2020 07:00 am ET
Vanda Pharmaceuticals Announces Virtual 2020 Stockholder Meeting
WASHINGTON, May 26, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA), announced today that Vanda will hold its 2020 Annual Meeting of Stockholders (the "2020 Annual Meeting") in a virtual-only format due to public health concerns related to the COVID-19 pandemic and to protect the health and well-being of its stockholders, directors, employees and the public. As previously announced, the 2020 Annual Meeting will be held on June 11, 2020, at 9:00 a.m. Eastern Time.
May 20, 2020 05:20 pm ET
Vanda Pharmaceuticals Wins Motion To Dismiss False Claims Act Lawsuit
WASHINGTON, May 20, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Federal District Court in Washington D.C. granted Vanda's motion to dismiss a False Claims Act lawsuit filed against the company.
May 20, 2020 10:45 am ET
Vanda Pharmaceuticals CEO's Proposal on Clinical Trial Data Sharing, COVID-19 and Remdesivir
WASHINGTON, May 20, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today released a letter (below) from Mihael H. Polymeropoulos, M.D., President and CEO of Vanda Pharmaceuticals, proposing an approach to Clinical Trial Data Sharing in order to facilitate discovery and clinical utility of COVID-19 therapeutics. Vanda is also involved in the development of therapeutic solutions for COVID-19 and currently in Phase III studies with tradipitant for the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19.
May 13, 2020 07:00 am ET
Vanda Pharmaceuticals Announces Agreement with FDA on Resubmission of the Application for HETLIOZ® for the Treatment of Patients with Smith-Magenis Syndrome
WASHINGTON, May 13, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that following the completion of a Type A Meeting with the U.S. Food and Drug Administration (FDA) on May 8, 2020, it has reached agreement with the FDA to resubmit its application for HETLIOZ® (tasimelteon) for the treatment of Smith-Magenis Syndrome (SMS).  As previously disclosed, Vanda received a Refusal to File letter from the FDA on March 12, 2020.  The Type A Meeting resolved the outstanding issues regarding the filing of the application.  Vanda plans to resubmit as soon as possi
May 06, 2020 04:01 pm ET
Vanda Pharmaceuticals Reports First Quarter 2020 Financial Results
WASHINGTON, May 6, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2020.
Apr 29, 2020 04:05 pm ET
Vanda Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 6, 2020
WASHINGTON, April 29, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2020 on Wednesday, May 6, 2020, after the market closes.  
Apr 15, 2020 04:15 pm ET
Vanda Pharmaceuticals Announces Initiation of "CALYPSO" to Study the Role of Genetic Variation in COVID-19 Infections in Collaboration With University of Washington Medicine
WASHINGTON, April 15, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the initiation of the CALYPSO program to study the role that human genetic variations play in SARS-CoV-2 ("COVID-19") infection and disease progression. As a part of the CALYPSO program, Vanda will collaborate with University of Washington School of Medicine and its Virology Lab on a pharmacogenetics study in patients with COVID-19. The study will focus on the sequencing of the genome of individual patients, as well as the COVID-19 virus, and the identification of genetic factors that
Apr 15, 2020 04:05 pm ET
Vanda Pharmaceuticals, Northwell Health Conduct ODYSSEY Trial In Patients With Severe COVID-19 Pneumonia
WASHINGTON, April 15, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and Northwell Health's research arm, The Feinstein Institutes for Medical Research, today announced enrollment of the first patient in Vanda's clinical trial, ODYSSEY VLY-686-3501 (NCT04326426), yesterday at Lenox Hill Hospital in New York City.
Apr 08, 2020 04:05 pm ET
Vanda Pharmaceuticals Inc. And The University of Illinois at Chicago Announce Partnership To Identify Novel Antivirals Against COVID-19
WASHINGTON, April 8, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) and the University of Illinois at Chicago (UIC) today announced a research partnership focused on the investigation of small molecules with the potential to treat COVID-19. The collaboration will include the use of a high-throughput screening assay to identify small molecules that may prevent cathepsin-L cleavage of SARS-CoV-2 (COVID-19) glycoproteins that are required for viral processing in the host cell.
Apr 02, 2020 01:36 pm ET
Vanda Pharmaceuticals Announces the Initiation of ODYSSEY, an FDA Approved Clinical Study of Tradipitant in Hospitalized Patients with Severe COVID-19 Pneumonia
WASHINGTON, April 2, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) today announced the initiation of clinical study, ODYSSEY VLY-686-3501, in hospitalized patients with COVID-19. The novel SARS-CoV-2 coronavirus is associated with a lower respiratory tract inflammation that often progresses to Acute Respiratory Distress Syndrome ("ARDS") requiring mechanical ventilation.
Nov 06, 2019 03:01 pm ET
Vanda Pharmaceuticals Reports Third Quarter 2019 Financial Results
WASHINGTON, Nov. 6, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2019.
Oct 30, 2019 04:30 pm ET
Vanda Pharmaceuticals to Announce Third Quarter 2019 Financial Results on November 6, 2019
WASHINGTON, Oct. 30, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2019 and provide a general business overview, on Wednesday, November 6, 2019, after the market closes. 
Oct 28, 2019 04:30 pm ET
Vanda Pharmaceuticals Appoints Anne Sempowski Ward to Board of Directors
WASHINGTON, Oct. 28, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Anne Sempowski Ward has joined the company's Board of Directors, effective October 28, 2019. Following Ms. Ward's appointment, Vanda's Board of Directors is now comprised of six directors.
Oct 23, 2019 04:01 pm ET
Vanda Announces New Study Results Showing a High Degree of Inbreeding in Beagle Dogs
WASHINGTON, Oct. 23, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced results of a comparative genomics study presented at the 2019 American Society of Human Genetics (ASHG) conference on October 19, 2019, entitled "Using Patterns in Regions of Homozygosity to Evaluate the Use of Dogs as Preclinical Models in Human Drug Development".
Oct 16, 2019 04:01 pm ET
Vanda Applauds White House Issuance of Executive Orders Requiring Federal Agencies to be Transparent in Policymaking and Enforcement
WASHINGTON, Oct. 16, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients, urges federal agencies, particularly the U.S. Food and Drug Administration (FDA), to comply with the release of the White House Executive Orders encouraging transparency and accountability when guidance documents are issued without the notice-and-comment rulemaking process required under the Administrative Procedure Act.
Sep 11, 2019 05:20 pm ET
Vanda Pharmaceuticals Applauds the EPA's Landmark Commitment to Eliminate Animal Testing and Urges the Food and Drug Administration to End Unnecessary and Scientifically Flawed Animal Toxicity Studies
WASHINGTON, Sept. 11, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients, commends the U.S. Environmental Protection Agency (EPA) for yesterday's pledge "to aggressively reduce animal testing" with the goal of "completely eliminating them by 2035." The EPA also shared that it has provided grants to identify and validate alternative testing methods. 
Aug 21, 2019 07:00 am ET
Vanda Pharmaceuticals Announces the Appointments of a Chief Corporate Affairs and Communications Officer and a Chief Marketing Officer
WASHINGTON, Aug. 21, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients, today announced that it has named Aranthan "AJ" Jones II as its Chief Corporate Affairs and Communications Officer and Joakim "Kim" Wijkstrom as its Chief Marketing Officer. Mr. Jones II and Mr. Wijkstrom will report directly to Mihael H. Polymeropoulos, M.D., Vanda's President and CEO. 
Aug 19, 2019 07:00 am ET
Vanda Pharmaceuticals FDA Update for HETLIOZ® in the Treatment of Jet Lag Disorder
WASHINGTON, Aug. 19, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that on August 16 2019, it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) as part of its ongoing review of Vanda's supplemental New Drug Application (sNDA) for HETLIOZ® (tasimelteon) for the treatment of Jet Lag Disorder (JLD).
Jul 31, 2019 04:01 pm ET
Vanda Pharmaceuticals Reports Second Quarter 2019 Financial Results
WASHINGTON, July 31, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2019.
Jul 29, 2019 02:19 pm ET
Shareholder Alert: Robbins Arroyo LLP: Vanda Pharmaceuticals Inc. (VNDA) Sued for Misleading Investors
Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) filed a derivative complaint against the company's officers and directors for breaches of fiduciary duties, unjust enrichment, and waste of corporate assets beginning in November 2015. Vanda Pharmaceutical
Jul 22, 2019 04:01 pm ET
Vanda Pharmaceuticals to Announce Second Quarter 2019 Financial Results on July 31, 2019
WASHINGTON, July 22, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2019 on Wednesday, July 31, 2019, after the market closes.
Jul 22, 2019 07:00 am ET
Vanda Pharmaceuticals FDA Update for HETLIOZ® in the Treatment of Jet Lag Disorder
WASHINGTON, July 22, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that on July 19, 2019, it received a notification from the U.S. Food and Drug Administration (FDA) stating that as part of its ongoing review of Vanda's supplemental New Drug Application (sNDA) for HETLIOZ® (tasimelteon) for the treatment of Jet Lag Disorder, the FDA has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time. No deficiencies were disclosed by the FDA in this notification, and the FDA stated that this notific
Jul 16, 2019 04:15 pm ET
Tradipitant Effective in Preventing Motion Sickness
WASHINGTON, July 16, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that tradipitant, a neurokinin-1 receptor antagonist, was effective in treating motion sickness in a clinical study conducted in the Pacific Ocean.
Jul 16, 2019 03:35 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Vanda Pharmaceuticals Inc. – VNDA
Levi & Korsinsky announces it has commenced an investigation of Vanda Pharmaceuticals Inc. (NASDAQGM: VNDA) concerning possible breaches of fiduciary duty. To obtain additional information, go to: http://www.zlkdocs.com/VNDA-Info-Request-Form-7728...
May 22, 2019 04:01 pm ET
Tradipitant in the Treatment of Gastroparesis: Vanda Presents Clinical Trial Results at DDW 2019
WASHINGTON, May 22, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (Nasdaq: VNDA) today announced the results of the Phase II study of tradipitant in gastroparesis were presented at Digestive Disease Week® (DDW) 2019 in San Diego, CA. 
May 01, 2019 04:01 pm ET
Vanda Pharmaceuticals Reports First Quarter 2019 Financial Results
WASHINGTON, May 1, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2019.
Apr 25, 2019 11:06 am ET
CLASS ACTION UPDATE for VNDA, CRCM, ARA and INVVY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Apr 25, 2019 10:00 am ET
FRIDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Vanda Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Vanda Pharmaceuticals Inc. (“Vanda” or “the Company”) (NASDAQ: VNDA) for violations of §§10(b) and 20(a) of the Securities...
Apr 24, 2019 04:30 pm ET
Vanda Pharmaceuticals Appoints Phaedra Chrousos to Board of Directors
WASHINGTON, April 24, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that Phaedra Chrousos has joined Vanda's Board of Directors, effective April 23, 2019. Following Ms. Chrousos' appointment, Vanda's Board of Directors is now comprised of six directors.
Apr 24, 2019 04:06 pm ET
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Vanda Pharmaceuticals Inc. Investors (VNDA)
Glancy Prongay & Murray LLP (“GPM”), a global investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors that acquired Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA) securities...
Apr 23, 2019 05:54 pm ET
VANDA FRIDAY DEADLINE: Rosen Law Firm Reminds Vanda Pharmaceuticals Inc. Investors of Important April 26th Deadline in First-Filed Case – VNDA
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Vanda Pharmaceuticals Inc. from November 4, 2015 through February 11, 2019, inclusive (the “Class Period”) of the important April 26, 2019 lead plaintiff...
Apr 22, 2019 10:05 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AMRN, VNDA, WTW and APYX
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Apr 19, 2019 07:14 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Vanda Pharmaceuticals Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the April 26, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ: 
Apr 18, 2019 04:30 pm ET
Vanda Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019
WASHINGTON, April 18, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2019 on Wednesday, May 1, 2019, after the market closes.  
Apr 18, 2019 02:05 pm ET
SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Vanda Pharmaceuticals Inc. – VNDA
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) from November 4, 2015 through February 11, 2019, inclusive (the “Class Period”). The...
Apr 18, 2019 10:18 am ET
SHAREHOLDER ALERT: VNDA SYNH WSR FSNN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Apr 18, 2019 06:30 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vanda Pharmaceuticals, Syneos, Weight Watchers, and Mattel and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Vanda Pharmaceuticals Inc., Syneos Health, Inc., Weight Watchers International, Inc., and Mattel, Inc.  Stockholders have...
Apr 17, 2019 04:11 pm ET
A Securities Class Action Has Been Filed Against Vanda; Block & Leviton LLP Encourages Shareholders to Contact the Firm
Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, informs investors that there has been a class action lawsuit filed against Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA)...
Apr 17, 2019 09:38 am ET
CLASS ACTION UPDATE for T, VNDA, EB and CRCM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Apr 16, 2019 06:03 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. – VNDA
Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals, Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Apr 16, 2019 03:00 pm ET
Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action Against Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH)
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Apr 16, 2019 09:59 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of T, VNDA, USX and BV
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Apr 15, 2019 05:43 pm ET
VNDA APRIL 26th DEADLINE: Rosen Law Firm Files Securities Class Action Lawsuit Against Vanda Pharmaceuticals Inc.; Encourages Investors With Losses In Excess of $100K to Contact the Firm – VNDA
Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) from November 4, 2015 through February 11, 2019, inclusive (the...
Apr 13, 2019 03:46 pm ET
INVESTOR ALERT: Kaskela Law LLC Announces Important Shareholder Class Action Lawsuit Deadlines – VNDA, SYNH, BPI and USX
Kaskela Law LLC announces that shareholder class action lawsuits have been filed against Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), Syneos Health, Inc. (Nasdaq: SYNH), Zovio Inc. f/k/a Bridgepoint Education, Inc. (NYSE: BPI) and U.S. Xpress...
Apr 11, 2019 03:06 pm ET
VNDA APR 26 DEADLINE: Zhang Investor Law Reminds of Deadline in Class Action Against Vanda Pharmaceuticals Inc. – VNDA
Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) from November 4, 2015 through February 11, 2019, inclusive (the “Class Period”). The lawsuit...
Apr 11, 2019 06:00 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vanda Pharmaceuticals, Syneos, Weight Watchers, and Mattel and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Vanda Pharmaceuticals Inc., Syneos Health, Inc., Weight Watchers International, Inc., and Mattel, Inc.  Stockholders have...
Apr 10, 2019 04:10 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm
NEW YORK, April 10, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Vanda Pharmaceuticals, Inc. ("Vanda" or the "Company") (NASDAQ:VNDA) of the April 26, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Apr 10, 2019 10:53 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of SPB, TAP, VNDA and CNDT
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Apr 09, 2019 05:57 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Vanda Pharmaceuticals, Inc. ("Vanda" or the "Company")(NASDAQ:VNDA) of the April 26, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Apr 09, 2019 03:30 pm ET
SHAREHOLDER ALERT: STMP T VNDA NTNX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Apr 09, 2019 03:00 pm ET
Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action Against Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH)
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Apr 09, 2019 11:00 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of VNDA, SYNH, UMC and NIO
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Apr 08, 2019 07:07 pm ET
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In AMRN, KHC, DPLO or VNDA To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, encourages investors in the following companies to contact the firm: Company: Amarin Corporation (NASDAQ:AMRN)Lead Plaintiff Deadline: April 23, 2019Class Period: September 24, 2018...
Apr 08, 2019 10:52 am ET
CLASS ACTION UPDATE for VNDA, CTL, NIO and CRBP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Apr 07, 2019 09:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. – VNDA
Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals, Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980....
Apr 06, 2019 01:10 pm ET
INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed Against Vanda Pharmaceuticals Inc. and Encourages Investors to Contact the Firm Before April 26
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of New York on behalf of those who acquired Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ:
Apr 04, 2019 04:00 pm ET
Safirstein Metcalf LLP Announces That A Class Action Has Been Filed Against Vanda Pharmaceuticals Inc. - VNDA
Safirstein Metcalf LLP announces that a class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ: VNDA) between November 4, 2015 and February...
Apr 04, 2019 11:00 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of VNDA, CVS, WTW and BPI
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Apr 04, 2019 06:00 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vanda Pharmaceuticals, Syneos, Weight Watchers, and Mattel and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Vanda Pharmaceuticals Inc., Syneos Health, Inc., Weight Watchers International, Inc., and Mattel, Inc.  Stockholders have...
Apr 03, 2019 05:42 pm ET
SHAREHOLDER ALERT: STMP VNDA SYNH UMC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Apr 03, 2019 04:34 pm ET
Hagens Berman Reminds Vanda Pharmaceuticals (VNDA) Investors of April 26, 2019 Lead Plaintiff Deadline and Encourages Investors to Contact the Firm
SAN FRANCISCO, April 3, 2019 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP reminds investors in Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) of the April 26, 2019 Lead Plaintiff deadline in the pending securities class action.  If you purchased or otherwise acquired Vanda securities between November 4, 2015 and February 11, 2019 (the "class period") and suffered losses contact Hagens Berman Sobol Shapiro LLP.  For more information about the case or to inquire about serving as Lead Plaintiff click
Apr 03, 2019 02:58 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Vanda Pharmaceuticals, Inc. ("Vanda" or the "Company")(NASDAQ:VNDA) of the April 26, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Apr 03, 2019 11:36 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of VNDA, SYNH, CRBP and NTNX
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Apr 02, 2019 05:46 pm ET
VNDA APRIL 26th DEADLINE: Rosen Law Firm Reminds Vanda Pharmaceuticals Inc. Investors of Important Deadline in First-Filed Case – VNDA
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Vanda Pharmaceuticals Inc. from November 4, 2015 through February 11, 2019, inclusive (the “Class Period”), of the important April 26, 2019 lead plaintiff...
Apr 02, 2019 05:33 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Vanda Pharmaceuticals, Inc. ("Vanda" or the "Company")(NASDAQ:VNDA) of the April 26, 2019 deadline to seek the role of lead plaintiff in a federal securities class...
Apr 01, 2019 10:48 am ET
CLASS ACTION UPDATE for STMP, VNDA, NIO and CRBP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Mar 29, 2019 01:39 pm ET
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Vanda Pharmaceuticals Inc.
Law Offices of Howard G. Smith reminds investors of the upcoming April 26, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA) securities between November 4, 2015 and February 11, 2019
Mar 29, 2019 10:00 am ET
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Vanda Pharmaceuticals Inc. Investors (VNDA)
Glancy Prongay & Murray LLP (“GPM”), a global investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors that acquired Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA) securities...
Mar 28, 2019 06:50 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Vanda Pharmaceuticals Inc. Investors
Law Offices of Howard G. announces that a class action lawsuit has been filed on behalf of investors who purchased Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA) securities between November 4, 2015 and February 11, 2019,...
Mar 28, 2019 04:24 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. – VNDA
Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals, Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980....
Mar 28, 2019 11:03 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ZIV, TAP, KHC and VNDA
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Mar 28, 2019 09:30 am ET
Hagens Berman Reminds Vanda Pharmaceuticals (NASDAQ: VNDA) Investors of the April 26, 2019 Lead Plaintiff Deadline and Unsealed Government Lawsuit
Hagens Berman Sobol Shapiro LLP reminds investors in Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) of the April 26, 2019 Lead Plaintiff deadline in the pending securities class action.  If you purchased or otherwise acquired Vanda securities between...
Mar 28, 2019 07:00 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vanda Pharmaceuticals, AVEO Pharmaceuticals, Stamps.com, and Syneos and Encourages Investors to Contact
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Vanda Pharmaceuticals Inc., AVEO Pharmaceuticals, Inc., Stamps.com Inc., and Syneos Health, Inc.  Stockholders have until the...
Mar 27, 2019 06:25 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Vanda Pharmaceuticals, Inc. ("Vanda" or the "Company")(NASDAQ:VNDA) of the April 26, 2019 deadline to seek the role of lead plaintiff in a federal securities class...
Mar 26, 2019 04:02 pm ET
SHAREHOLDER ALERT: STMP VNDA USX CRBP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 26, 2019 03:38 pm ET
Block & Leviton LLP Reminds Shareholders of Important Deadlines: AMRN, ASTE, INGN, VNDA
Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, reminds investors of the important deadlines listed below. If you have purchased or otherwise acquired any of the securities listed below,...
Mar 26, 2019 03:00 pm ET
Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action Against Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH)
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Mar 26, 2019 02:58 pm ET
VNDA DEADLINE: Zhang Investor Law Reminds of Deadline in Class Action Against Vanda Pharmaceuticals Inc. – VNDA
Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) from November 4, 2015 through February 11, 2019, inclusive (the “Class Period”). The lawsuit...
Mar 26, 2019 11:41 am ET
CLASS ACTION UPDATE for SPB, STMP, VNDA and SYNH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Mar 25, 2019 10:22 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AVP, VNDA, CVS and INGN
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 21, 2019 07:26 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. – VNDA
Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals, Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Mar 21, 2019 03:00 pm ET
Bronstein, Gewirtz & Grossman, LLC Class Action Reminder Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Diplomat Pharmacy, Inc. (DPLO) - 
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Mar 21, 2019 10:50 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CORT, CAG, VNDA and INGN
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Mar 20, 2019 08:47 pm ET
SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Vanda Pharmaceuticals Inc. – VNDA
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) from November 4, 2015 through February 11, 2019, inclusive (the “Class Period”). The...
Mar 20, 2019 03:52 pm ET
CLASS ACTION ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Significant Losses From Investment In Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) To Contact Bro
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of purchasers of Vanda...
Mar 20, 2019 09:32 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of GSM, MU, VNDA and WTW
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 19, 2019 04:28 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Vanda Pharmaceuticals, Inc. ("Vanda" or the "Company") (NASDAQ:VNDA) of the April 26, 2019 deadline to seek the role of lead plaintiff in a federal securities class...
Mar 19, 2019 12:13 pm ET
SHAREHOLDER ALERT: AVP DPLO VNDA CTL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 19, 2019 11:06 am ET
April 26th Vanda (VNDA) Deadline: Bernstein Liebhard LLP Reminds Investors of the Important Upcoming Deadline in the Shareholder Class Action Lawsuit Against Vanda Pharmaceuticals Inc. – VNDA
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the important April 26, 2019 lead plaintiff deadline in the shareholder class action lawsuit against Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”)...
Mar 17, 2019 10:10 am ET
CLASS ACTION UPDATE for GSM, WRCDF, CAG and VNDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Mar 15, 2019 07:27 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc. – VNDA
Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals, Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980....
Mar 14, 2019 03:00 pm ET
Vanda Pharmaceuticals Inc. (VNDA) Bronstein, Gewirtz & Grossman, LLC Class Action Update and Deadline: April 26, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit against Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA) and certain of its officers, on behalf of shareholders who...
Mar 14, 2019 11:00 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of GSM, VALE, VNDA and USX
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Mar 13, 2019 05:55 pm ET
VNDA APRIL 26th DEADLINE ALERT: Rosen Law Firm Reminds Vanda Pharmaceuticals Inc. Investors of Important Deadline in First-Filed Case; Encourages Investors With Losses in Excess of $100K to Contact th
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) from November 4, 2015 through February 11, 2019, inclusive (the “Class Period”) of the important April 26, 2019...
Mar 13, 2019 03:34 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of GSM, VALE, VNDA and NIO
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 13, 2019 10:07 am ET
SHAREHOLDER ALERT: ATVI AMRN VNDA USX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 11, 2019 03:39 pm ET
Vanda (VNDA) Class Action Lawsuit: Bernstein Liebhard LLP Announces a Securities Class Action Lawsuit Against Vanda Pharmaceuticals Inc. – VNDA
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Vanda Pharmaceuticals Inc. (“Vanda” or the...
Mar 11, 2019 11:19 am ET
CLASS ACTION UPDATE for AXGN, MKL, VALE and VNDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Mar 08, 2019 12:00 pm ET
Vanda Pharmaceuticals Inc. (VNDA) Bronstein, Gewirtz & Grossman, LLC Class Action Update and Deadline: April 26, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ: VNDA) and certain of its officers, on behalf of...
Mar 07, 2019 09:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. – VNDA
Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals, Inc. (“Diplomat” or the “Company”) (NASDAQ: VNDA).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Mar 07, 2019 07:39 pm ET
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Vanda Pharmaceuticals Inc. Investors (VNDA)
Glancy Prongay & Murray LLP (“GPM”), a global investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors that acquired Vanda Pharmaceuticals Inc. (“Vanda” or the “Company”) (NASDAQ:
Mar 07, 2019 05:39 pm ET
VNDA LAWSUIT ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Vanda Pharmaceuticals Inc. - VNDA
NEW YORK, March 7, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) from November 4, 2015 through February 11, 2019, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Vanda investors under the federal securities laws.
Mar 07, 2019 04:38 pm ET
Vanda (VNDA) Class Action Lawsuit: Bernstein Liebhard LLP Announces A Securities Class Action Lawsuit Against Vanda Pharmaceuticals Inc. – VNDA
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Vanda Pharmaceuticals Inc. (“Vanda” or the...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.